Lumos Diagnostics: AU$4.75m Placement Completed, SPP Launched

Lumos Diagnostics (ASX: LDX) has successfully completed an AU$4.75 million institutional placement and simultaneously launched a Share Purchase Plan (SPP). The institutional placement received firm commitments from existing institutional shareholders at a price of AU$0.07 per share. The company has set a target to generate an additional AU$4.75 million through the SPP, maintaining the same issue price as the placement.

The funds raised from both initiatives will be utilized for buying back outstanding convertible notes and to support general working capital requirements. Noteworthy highlights include Lumos recent achievement of US FDA regulatory clearance for its FebriDx point-of-care test, a significant operational turnaround with reduced operating costs over the past year, and a strategic partnership with Hologic involving development contracts for new and existing products.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com